Ceva Animal Health unveils Ceva Genesys, announces strategic expansions 

FRANCE – Ceva Animal Health, a global leader in animal health solutions, has launched Ceva Genesys, an advanced innovation for broiler production aimed at improving flock uniformity and sustainability. 

This cutting-edge technology enables precise male and female separation at hatch, optimising poultry-rearing processes to meet the growing global demand for poultry meat while addressing environmental challenges.  

As a specialist in hatchery technology, Ceva has continuously advanced poultry production systems. 

“Since 2011, Ceva has worked side-by-side with the poultry industry to modernise hatchery processes,” stated Sylvain Comte, Poultry Franchise Director at Ceva Animal Health. “With Ceva Genesys, we bring another innovative solution to the table, enabling producers to enhance performance across the entire production chain.”  

By ensuring accurate gender sorting, Ceva Genesys improves flock homogeneity, facilitating tailored feeding and care strategies for optimal growth and productivity. 

Several commercial projects have already implemented this technology globally since the third quarter of 2024.  

Investment in vaccine manufacturing expansion  

In other news, Ceva recently announced the construction of a 7,000 m² state-of-the-art vaccine production facility in Monor, Hungary. 

The facility will focus on fermentation-based multicomponent inactivated vaccines, strengthening the capacity of Ceva Phylaxia, a historic campus with over a century of vaccine development expertise.  

Expected to begin operations by the end of 2026, the facility will produce over 8 billion vaccine doses annually, reinforcing Ceva’s position as a pioneer in vaccine innovation, including vector vaccines for poultry and the first animal mRNA platform.  

“This project reflects our ambition to build a promising future for our company, employees, and partners while strengthening our research and development capabilities,” said Marc Prikazsky, Chairman and CEO of Ceva.  

This investment aligns with the rapidly growing global livestock vaccine market, which is expected to expand from US$6.01 billion in 2024 to US$9.80 billion by 2032 at a CAGR of 6.3%. 

Adding to its strategic milestones, Ceva announced the appointment of Christophe Bailet as Group Chief Financial Officer. 

Bailet brings extensive international financial expertise and will oversee the company’s next refinancing cycle, ensuring resources align with its ambitious growth plans.  

“I am excited to contribute to Ceva’s mission of innovation and to address pressing challenges in animal health,” Bailet remarked.  

Sign up HERE to receive our email newsletters with the latest news updates and insights from Africa and the World and follow us on our WhatsApp channel for updates.